Significantly, tumors with mutations in the DNA repair protein PTEN account for 4–8% of all NSCLCs and it has been shown that PTEN mutant tumor cells are sensitive to PARP inhibitors, expanding the number of lung cancer patients this therapy may benefit (113, 114). The gene discussed is PTEN; the disease is lung cancer.